AML patients have high response rate with vorinostat added to treatment
Tuesday, December 13, 2011 - 04:00
in Health & Medicine
Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.